178 related articles for article (PubMed ID: 37100349)
1. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
2. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
4. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
5. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
Caritis SN; Dodeja P; Sharma S; Zhao W; Venkataramanan R
Am J Obstet Gynecol; 2024 Apr; ():. PubMed ID: 38670444
[TBL] [Abstract][Full Text] [Related]
6. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
7. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
8. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
9. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
10. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
11. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
[TBL] [Abstract][Full Text] [Related]
12. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
[TBL] [Abstract][Full Text] [Related]
14. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ultrasound-indicated cerclage in twin pregnancies: a retrospective case-control study matched by cervical length.
Qiu L; Lv M; Chen C; Li J; Zhao B; Luo Q
Am J Obstet Gynecol MFM; 2023 Mar; 5(3):100847. PubMed ID: 36638868
[TBL] [Abstract][Full Text] [Related]
16. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Eke AC; Sheffield J; Graham EM
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
[TBL] [Abstract][Full Text] [Related]
18. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
;
Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078
[TBL] [Abstract][Full Text] [Related]
19. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
20. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
